- Company
- Amgen-CKD ink co-promotion deal on Evenity
- by Nov 16, 2020 06:03am
- On Nov. 12, Amgen Korea (General Manager Noh Sang-kyung) and Chong Kun Dang (CEO Kim Young-joo) announced they signed a co-promotion agreement on a novel osteoporosis drug Evenity (romososumab) on Nov. 11. The two companies also renewed the Prolia (denosumab) co-promotion deal as well. According to the agreement, Amgen Korea would fo
- Policy
- Detailed review for COVID-19 tx budget are insufficient
- by Lee, Jeong-Hwan Nov 16, 2020 06:02am
- The National Assembly's Health and Welfare Committee was found to have insufficient details of the detailed review of the new budget of &8361;965 billion, which accounted for the largest volume of the COVID-19-related budget, before the resolution of the budget under its jurisdiction next year. Although it accounts for the highest budget
- Policy
- RWD is useful for shortening new drug's approval period
- by Lee, Hye-Kyung Nov 16, 2020 06:02am
- Opinion was raised that the use of RWD (Real Word Data) owned by The HIRA could accelerate and improve domestic drug development and new drug approval. Prof. Hyung-ki Lee and Ph.D student Yoo-min Jeon published their contributions in the HIRA Big Data Brief on the subject of 'The possibility of utilizing HIRA big data for efficient design,
- Policy
- COVID-19 vaccine likely to be approved w/o clinical trials
- by Lee, Tak-Sun Nov 16, 2020 06:02am
- The COVID-19 vaccine candidate material, which is showing a rapid pace in commercialization, is expected to undergo bridging study after the market because clinical trials are difficult in Korea. The clinical trial is difficult because, ironically, there are few COVID-19 confirmed cases in Korea. On the 10th, Pfizer USA and BioNTech, G
- Product
- A professor reserves thoughts on “90% effective vaccine"
- by Kim, Min-Gun Nov 16, 2020 06:02am
- A U.S. pharmaceutical company Pfizer has attracted a global attention as it announced a COVID-19 vaccine in development has demonstrated an efficacy rate above 90 percent in early results from a Phase 3 trial. One of vaccine experts in South Korea, Professor Seol Dai Wu at Chung-Ang University College of Pharmacy spoke on Nov. 11 at an
- Company
- Dong-A ST introduces SHR-1701 in China
- by Chon, Seung-Hyun Nov 16, 2020 06:02am
- Dong-A ST announced on the 11th that it has signed a contract with Jiangsu Hengrui Medicine to introduce the next-generation immune anticancer drug 'SHR-1701' in Korea. With this contract, Dong-A ST has secured the exclusive domestic development and sales rights of fusion protein, which is undergoing phase I and II clinical trials in China by
- Policy
- The introduction of vaccine will be discussed after results
- by Lee, Tak-Sun Nov 12, 2020 06:28am
- The MFDS said it would discuss the final clinical results of Pfizer's COVID-19 vaccine, which showed the potential for clinical success, for introduction. Seo Kyung-won, the head of the drug review department at the MFDS, made such a statement at a briefing on the approval status of vaccines for the treatment of COVID-19 held on the 10th
- Policy
- Boryung introduced Symbenda's first generic in Korea
- by Lee, Tak-Sun Nov 12, 2020 06:19am
- Boryung introduces a generic drug which was reimbursed in 2 years ago. Boryung's Bendamustine HCl is the first generic for Symbenda. The MFDS approved Boryung's Bendamustine HCl on the 11th. It is a generic for Symbenda which was approved by Ezai Korea in 2011, and is the first generic in Korea. Symbenda was approved in 2011, but it took sev
- Opinion
- [Reporter’s View] ERP should be kept ‘voluntary-basis’
- by Nov 12, 2020 06:19am
- The pharmaceutical industry is bracing themselves as winter is coming with the management offering early retirement program (ERP). Lilly Korea, a South Korean branch of the U.S.-based Eli Lilly’, has presented the ERP plan to reduce a quarter of its sales force. It is its first ERP after three years since 2017. Only Lilly Korea has
- Policy
- Budget Subcommittee passes KRW 965 bln for COVID-19 vaccine
- by Lee, Jeong-Hwan Nov 12, 2020 06:19am
- The Budget and Accounting Evaluation Subcommittee of the National Assembly Health and Welfare Committee has deliberated and decided on the 2021 budget plans for the Ministry of Health and Welfare (MOHW), the Ministry of Food and Drug Safety (MFDS) and the Korea Disease Control and Prevention Agency (KDCA). The subcommittee explained the
